U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:U.S. Stem Cell Inc (USRM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10098
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
U.S. Stem Cell Inc (U.S. Stem Cell), formerly Bioheart, Inc, is a biotechnology company that focuses on the discovery, development and commercialization of cell based therapeutics products. The company repairs and replaces damaged or aged tissue, cells and organs and restoring their normal function. The company’s lead product MyoCell, is designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, to improve cardiac function in chronic heart failure patients. Its services includes the development of proprietary cell therapy products based on regenerative medicine and cell therapy training services, cell collection and cell storage services, sale of cell collection and treatment kits for humans and animals, and operation of a cell therapy clinic. U.S. Stem Cell is headquartered in Sunrise, Florida, the US.

U.S. Stem Cell Inc (USRM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
Private Equity 13
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Partnerships 14
Bioheart Forms Joint Venture with Walter Bell 14
Licensing Agreements 15
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
Debt Offering 18
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Acquisition 28
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc – Key Competitors 30
U.S. Stem Cell Inc – Key Employees 31
U.S. Stem Cell Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: USRM posts 25% nine month revenue increase from 3Q 2017 33
Aug 08, 2018: USRM posts profitable results for second quarter 2018 34
May 09, 2018: U.S. Stem Cell Reports First Quarter Results 35
Apr 16, 2018: USRM Reports 2017 Financial Results 36
Aug 09, 2017: U.S. Stem Cell Reports Most Successful Financial Performance in the Company’s History 37
Corporate Communications 38
Sep 11, 2018: USRM hires senior VP of US & international sales 38
Legal and Regulatory 39
Aug 28, 2017: FDA warns US Stem Cell Clinic of significant deviations 39
Product News 40
Mar 21, 2018: USRM Demonstrates 99% Reduction in Severity of Psoriasis Utilizing Autologous Stem Cells 40
Other Significant Developments 42
Apr 24, 2018: Market Demand for Stem Cell Treatments Driving Steady Increase in USRM Sales 42
Feb 06, 2018: USRM Seeing Explosive Increase in Demand for Stem Cell Therapy 43
Aug 28, 2017: U.S. Stem Cell Clinic Acknowledges Warning Letter By The FDA and Responds 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
U.S. Stem Cell Raises USD0.3 Million in Venture Financing 12
General American Capital to Invest up to USD5 Million in US Stem Cell 13
Bioheart Forms Joint Venture with Walter Bell 14
Bioheart Enters Into Licensing Agreement With Allan Wu For Cancer-Related Immunotherapy Products 15
Bioheart Enters Into Licensing Agreement With Invitrx Therapeutics 16
Bioheart Enters Into Licensing Agreement With Ageless Regenerative Institute For Adipose Cell Technology 17
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 12% Convertible Note Due 2016 18
U.S. Stem Cell Raises USD0.1 Million in Private Placement of 12% Convertible Note Due 2016 19
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 20
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 9.5% Notes 21
U.S. Stem Cell Raises USD0.04 Million in Private Placement of 8% Notes 22
U.S. Stem Cell Raises USD0.33 Million in Private Placement of 8% Notes 23
U.S. Stem Cell Raises USD0.1 Million in Private Placement of Notes 24
U.S. Stem Cell Raises USD0.13 Million in Private Placement of Notes 25
U.S. Stem Cell Raises USD0.25 Million in Private Placement of 8% Notes 26
U.S. Stem Cell Raises USD0.03 Million in Private Placement of 8% Notes 27
Bioheart to Acquire Pavillion Scientific 28
Bioheart to Invest in Ascyrus Medical 29
U.S. Stem Cell Inc, Key Competitors 30
U.S. Stem Cell Inc, Key Employees 31
U.S. Stem Cell Inc, Joint Venture 32

List of Figures
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
U.S. Stem Cell Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
U.S. Stem Cell Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[U.S. Stem Cell Inc (USRM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Murray & Roberts Holdings Ltd (MUR):企業の財務・戦略的SWOT分析
    Murray & Roberts Holdings Ltd (MUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • BLS AG:企業の戦略・SWOT・財務情報
    BLS AG - Strategy, SWOT and Corporate Finance Report Summary BLS AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Hargreaves Services Plc:企業の戦略・SWOT・財務分析
    Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vallourec SA:企業のM&A・事業提携・投資動向
    Vallourec SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Vallourec SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Great Wolf Resorts Inc:企業の戦略・SWOT・財務情報
    Great Wolf Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Great Wolf Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • AVEVA Group Plc:企業の戦略・SWOT・財務情報
    AVEVA Group Plc - Strategy, SWOT and Corporate Finance Report Summary AVEVA Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tenneco Inc. (TEN):企業の財務・戦略的SWOT分析
    Tenneco Inc. (TEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Harmonic Inc (HLIT):企業の財務・戦略的SWOT分析
    Harmonic Inc (HLIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Opthea Ltd (OPT):企業の財務・戦略的SWOT分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd, is a biotechnology company that develops novel biologic therapy for the treatment of eye diseases. The company carries out research and development of angiogenesis and vascular leakage-based treatments for cancer concentrating on vasc …
  • Arris International Plc:企業の戦略・SWOT・財務分析
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Dairyland Power Cooperative:発電所・企業SWOT分析
    Dairyland Power Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Smiths Group Plc (SMIN):医療機器:M&Aディール及び事業提携情報
    Summary Smiths Group Plc (Smiths Group) is a diversified technology company. It offers critical solutions for energy and process industries, medical devices and consumables, devices for detection and identification of security threats and contraband, solutions for high speed connectivity and compone …
  • Sartorius Stedim Biotech SA (DIM):企業の財務・戦略的SWOT分析
    Sartorius Stedim Biotech SA (DIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Phillips 66 Co (PSX):石油・ガス:M&Aディール及び事業提携情報
    Summary Phillips 66 Co (Phillips 66) is a diversified energy manufacturing and logistics company. It gathers, processes, transports, stores and markets natural gas and petroleum products such as gasoline, diesel, aviation fuel and lubricants. It also transports, fractionates and markets natural gas …
  • Electricity Generation Company of Bangladesh Ltd:企業の戦略的SWOT分析
    Electricity Generation Company of Bangladesh Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competit …
  • Slavneft-Megionneftegaz (MFGS):企業の財務・戦略的SWOT分析
    Summary Slavneft-Megionneftegaz (Megionneftegaz), a subsidiary of Slavneft, is an oil and gas company that operates oil fields. The company’s activities include appraisal of oil and gas fields, oil and gas production, and well drilling and operation. Megionneftegaz develops and introduces advanced t …
  • BioTex Inc:企業の製品パイプライン分析
    Summary BioTex Inc (BioTex) operates as a medical device company that designs, develops, manufactures and distributes electro-mechanical, optical and software based devices. The company offers sterile and non-sterile disposable products for surgical, non-surgical and interventional procedures in dia …
  • Univar Inc (UNVR):企業の財務・戦略的SWOT分析
    Univar Inc (UNVR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CanBas Co Ltd (4575)-製薬・医療分野:企業M&A・提携分析
    Summary CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that provides drugs. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It product under development is CBP501, a modified synthetic peptide enhancing the efficacy of …
  • Ineos Group AG:石油・ガス:M&Aディール及び事業提携情報
    Summary Ineos Group AG (Ineos), a subsidiary of INEOS Group Holdings SA, is a chemical manufacturing company. It manufactures and sells petrochemicals, specialty chemicals and oil products. The company’s products include ammonia, nitric acid, sea salt, esters, bio fuel, sulphuric acid, amino resin, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆